A study of 61 patients showed that Byetta, a diabetes drug from Amylin Pharmaceuticals and Eli Lilly and Co., decreased blood-sugar levels and reduced appetite better than Januvia, a rival medicine from Merck & Co. The findings demonstrate "a clear difference in the method of actions" between the two products amid confusion in the marketplace about their therapeutic qualities, one of the researchers said.

Full Story:

Related Summaries